The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts).
Giulio Metro
No relevant relationships to disclose
Simona Duranti
No relevant relationships to disclose
Rita Chiari
No relevant relationships to disclose
Chiara Bennati
No relevant relationships to disclose
Carmen Molica
No relevant relationships to disclose
Maria Francesca Currà
No relevant relationships to disclose
Chiara Scafati
No relevant relationships to disclose
Annamaria Siggillino
No relevant relationships to disclose
Antonella Flacco
No relevant relationships to disclose
Luca Marcomigni
No relevant relationships to disclose
Vienna Ludovini
No relevant relationships to disclose
Vincenzo Minotti
No relevant relationships to disclose
Lucio Crinò
No relevant relationships to disclose